[Comparative analysis of the safety of triple therapy with telaprevir between HCV monoinfected and HIV coinfected patients].
To know the possible differences in the toxicity profile of triple therapy with telaprevir between monoinfected and coinfected patients. A retrospective observational study (January 2012- November 2013) of patients with HCV genotype 1, both monoinfected and coinfected with HIV, who had completed 12 weeks of treatment with telaprevir. The necessary variables were collected to characterize patients and the treatment received. The classification was made according to the toxicity criteria of the Division of AIDS v.1.0. A descriptive and comparative statistical analysis using the SPSS v.15.0 software was performed. 100 patients were included, 41% coinfected with HIV. Cirrhosis rate was observed at higher coinfected patients (97.6% vs 52.5%, p <0.001). increased incidence in coinfected hyperbilirubinemia (51.2% vs 27.1% p = 0.012). TOXICITY grades: no differences in mild-moderate toxicity were observed between the two groups,while severe hyperbilirubinemia was higher in coinfected (26.8% (39.9% vs 12.2% p = 0.003) was observed, and dose adjustment of ribavirin (64.4% vs 26.8% p <0.001) in monoinfected patients. The study shows a similar toxicity profile between the two groups except for hyperbilirubinemia appears greater in coinfected patients (possibly related to the use of atazanavir) and less use of exogenous erythropoietin and dose reduction of ribavirin in them.